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Abstract
It is increasingly appreciated that oncogenic transformation alters cellular metabolism to facilitate 
cell proliferation, but less is known about the metabolic changes that promote cancer cell 
aggressiveness. Here, we analyzed metabolic gene expression in cancer cell lines and found that a 
set of high-grade carcinoma lines expressing mesenchymal markers shared a unique 44-gene 
signature, designated the “mesenchymal metabolic signature” (MMS). A FACS-based shRNA 
screen identified several MMS genes as essential for the epithelial-mesenchymal transition (EMT) 
but not for cell proliferation. Dihydropyrimidine dehydrogenase (DPYD), a pyrimidine-degrading 
enzyme, was highly expressed upon EMT induction and was necessary for cells to acquire 
mesenchymal characteristics in vitro and for tumorigenic cells to extravasate into the mouse lung. 
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This role of DPYD was mediated through its catalytic activity and enzymatic products, the 
dihydropyrimidines. Thus, we identify metabolic processes essential for the EMT, a program 
associated with the acquisition of metastatic and aggressive cancer cell traits.
Introduction
Alterations in cellular metabolism are now recognized as an emerging hallmark of cancer 
(Hanahan and Weinberg, 2011) ). Almost a century ago, Otto Warburg observed that, under 
aerobic conditions, tumor cells display increased glucose uptake and glycolytic rates 
compared to resting cells (reviewed in (Hsu and Sabatini, 2008; Ward and Thompson, 
2012)). Subsequently, many studies have revealed how this and other metabolic changes 
allow cancer cells to accumulate building blocks for the biosynthesis of macromolecules, 
while simultaneously maintaining energetic and redox balance (reviewed in (Cantor and 
Sabatini, 2012)). Whereas many of these mechanisms are shared with normal rapidly 
proliferating cells, in recent years cancer genomic data have revealed metabolic alterations 
that appear to occur only in specific tumor types. These changes include the loss of 
succinate dehydrogenase (SDH) or fumarate hydratase (FH) in certain renal cell carcinomas 
and other familial cancer syndromes (reviewed in (Gottlieb and Tomlinson, 2005)), mutation 
of isocitrate dehydrogenase (IDH) 1 or 2 in glioma, acute myeloid leukemias, and 
chondrosarcomas (Dang et al., 2009; Schulze and Harris, 2012), and amplification of 
phosphoglycerate dehydrogenase (PHGDH) in estrogen receptor (ER)-negative breast 
cancer and melanoma (Locasale et al., 2011; Possemato et al., 2011). These examples 
suggest that, in addition to fueling increased proliferation, cancer-associated alterations in 
metabolism can also satisfy tumor-specific demands.
Relatively few studies have examined the metabolic underpinnings of the cellular programs 
that increase cancer cell aggressiveness (Nomura et al., 2010; Ulanovskaya et al., 2013; 
Zhang et al., 2012). One such program is the epithelial-mesenchymal transition (EMT) 
(reviewed in (Nieto and Cano, 2012)) that operates in carcinoma cells and is thought to 
confer stem-like properties, such as enhanced survival, self-renewal, and anchorage-
independent growth, all of which contribute to increased aggressiveness in vivo (Scheel and 
Weinberg, 2011). Indeed, EMT markers are predictive for increased invasion, loss of 
differentiated characteristics, metastasis, and poor prognosis in a number of human tumor 
types (Nieto and Cano, 2012).
To understand how cellular metabolism contributes to these and other proliferation-
independent features of cancer, we created a framework for the systematic identification of 
metabolic alterations specific to particular tumor types, as well as those that may 
characterize high-grade malignancies. By analyzing metabolic gene expression patterns in a 
large number of cancer cell lines, we identified a metabolic gene signature that is present in 
high-grade tumors bearing mesenchymal markers. Among the enzymes encoded by these 
genes is dihydropyrimidine dehydrogenase (DPYD), which catalyzes the rate-limiting step 
in pyrimidine degradation and whose physiological role in cancer was previously unknown. 
We find that EMT-promoting transcription factors induce the expression of DPYD and that 
its products, the dihydropyrimidines, must accumulate for cells to undergo an EMT. These 
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findings reveal that the EMT induces a particular metabolic state and suggest that DPYD 
may have value as a diagnostic marker or therapeutic target in high-grade carcinomas.
Results
A mesenchymal-like metabolic gene expression signature in high-grade carcinoma cells
In order to study metabolic gene expression patterns in cancer, we used publicly available 
data to generate a database of mRNA expression profiles for 1,704 metabolic genes in 978 
human cancer cell lines (see Experimental Procedures) (Possemato et al., 2011). Aided by 
unsupervised hierarchical clustering, we organized the profiles into five distinct groups 
(Figure 1A and Table S1); for four of these groups, the basis for clustering was readily 
apparent (Figure 1B). One group consisted of melanoma cell lines, which uniquely express 
skin pigment biosynthesis genes. The cell lines in a second group were derived from 
hematopoietic system cancers (e.g., leukemia, lymphoma, and multiple myeloma) and, in a 
third, from neuroendocrine or neuroectodermal cancers (e.g., small cell lung cancer, 
medulloblastoma, neuroblastoma (Onganer et al., 2005; Parham, 2001)). A fourth group 
consisted mostly of epithelial cancer cell lines, in which cell lines originating from breast, 
liver, colon, kidney, etc. clustered together. These results indicate that patterns of metabolic 
gene expression are sufficient to organize most cancer cell lines by tissue-of-origin, 
suggesting that many cancers retain significant portions of the metabolic programs of their 
normal tissue counterparts.
The cell lines in the fifth group proved more difficult to classify, and thus were initially 
named the “mixed-lineage group” (Figure S1A). While this group contained almost all the 
cell lines derived from mesenchymal tumors (soft tissue sarcoma, osteosarcoma; 20% of the 
cell lines in this group) and glioblastomas, it also included a large number of carcinoma 
lines (e.g. non-small-cell lung, hepatocellular, and breast; 43% of the cell lines in this 
group). Notably, all the breast cancer lines in the mixed-lineage group were of the Basal B 
subtype, which are derived from high-grade carcinomas (Carey et al., 2010) (Figure 1C). 
Likewise, all the hepatocellular carcinoma (HCC) cell lines in this group were also derived 
from high-grade tumors (Park et al., 1995), and retained fewer of the metabolic gene 
expression features of normal liver than did the HCC lines that were in the epithelial group 
(Figure S1B). Such loss of epithelial and gain of mesenchymal characteristics has been 
associated with high-grade malignancy in a variety of carcinoma types (Brabletz, 2012). 
Moreover, several of the glioblastoma and the majority of Basal B breast cancer cell lines 
are known to bear mesenchymal characteristics (Kao et al., 2009; Verhaak et al., 2010). 
Thus, we thought it likely that the cell lines in the mixed-lineage group shared a common 
mesenchymal-like phenotype.
Indeed, Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) of ~17,000 genes 
showed that expression of the mesenchymal gene-set (EMT_UP) was significantly elevated 
in the mixed-lineage group relative to the other groups (FDR q-value<0.0001; Figure S1D). 
Furthermore, the mixed-lineage group had elevated expression of key mesenchymal markers 
(Mani et al., 2008), including vimentin (VIM), Snail family zinc finger 1 and 2 (SNAI1/2), 
N-cadherin (CDH2), Twist basic helix-loop-helix transcription factor 1 (TWIST1), and the 
zinc finger E-box binding homeobox 1 (ZEB1) transcription factor (Figure 1D). Lastly, the 
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epithelial markers claudin 1 (CLDN1) and E-cadherin (CDH1) were expressed at low levels 
in this group (Figure 1D). Collectively, these data suggest that the cell lines in the mixed-
lineage group, regardless of tissue of origin, display a mesenchymal-like gene expression 
profile. Accordingly, we refer hereafter to the mixed-lineage group as the mesenchymal 
group of cell lines.
Identification of a mesenchymal metabolic gene expression signature
We identified a mesenchymal metabolic signature (MMS), composed of 44 metabolic genes 
associated with diverse metabolic pathways, as highly and differentially expressed in the 
mesenchymal group of cell lines relative to the other groups (see Experimental Procedures) 
(Table 1 and Figure 2A). The MMS is particularly enriched for glycan biosynthesis genes 
(36% of the genes in the set), including glutamine-fructose-6-phosphate aminotransferase 
(GFPT2) and acetylhexosamine pyrophosphorylase (UAP1), which encode the rate-limiting 
and endpoint enzymes of the hexosamine biosynthetic pathway (HBP), respectively (Elbein 
et al., 2004; Zhang, 2004). The HBP end product, UDP-GlcNAc, is used by the enzyme O-
GlcNac transferase (OGT) as a donor substrate to modify proteins via covalent attachment 
of GlcNAc to serine and/or threonine residues (Ma and Vosseller, 2013). Of special interest, 
this modification plays an important role in mesenchymal cells by stabilizing the EMT-
inducing transcription factor SNAI1, which in turn down-regulates the key epithelial marker 
CDH1 (Park et al., 2010). The MMS list includes other genes with known connections to 
cancer aggressiveness, such as ecto-5′-nucleotidase (NT5E, also known as CD73), a 
mesenchymal stem cell marker (Stagg et al., 2010), ectonucleotide pyrophosphatase/
phosphodiesterase 2 (ENPP2, autotaxin), which promotes cell migration and metastasis 
(Benesch et al., 2014), and monoacylglycerol lipase (MGLL), which enhances cancer cell 
aggressiveness through the production of signaling lipids (Nomura et al., 2010). These 
examples suggest that the remaining MMS genes may also play an important role in the 
mesenchymal phenotype and/or aggressiveness of certain cancer cells.
We found that the MMS genes were significantly upregulated in cell lines that express 
known mesenchymal markers (Figure 2B, left). For example, this gene set is upregulated in 
cell lines derived from Basal B breast cancer and high-grade HCC relative to their luminal 
and low-grade counterparts, respectively (Figure 2C). Quantitative PCR and immunoblotting 
confirmed the overexpression of several individual MMS genes, including nicotinamide N-
methyltransferase (NNMT) and DPYD, in high-grade breast cancer and HCC cell lines 
(Figure 2D and 2E), which also expressed mesenchymal markers, such as ZEB1 and 
TWIST1, and low levels of CDH1 (Figure S2B).
We next asked if MMS gene expression correlates with that of known mesenchymal markers 
in primary human tumors as well as in cancer cell lines. From a database of expression 
profiles for 1,460 human primary tumors, including many of mesenchymal origin, we 
identified tumors with high expression of known mesenchymal markers (see Experimental 
Procedures) (Figure S2A). In such tumors, the MMS genes were significantly more highly 
expressed than in tumors not expressing these markers (Figure 2B and S2A). Thus, MMS 
gene expression correlates with that of known mesenchymal markers in both cancer cell 
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lines and tumors, suggesting that a particular metabolic program characterizes the 
mesenchymal cell state.
EMT-dependent induction of mesenchymal metabolic signature genes
Given the high expression of MMS genes in mesenchymal-like relative to epithelial cancer 
cell lines, we hypothesized that the EMT program may directly affect the expression of these 
genes. To investigate this possibility, we examined engineered human mammary epithelial 
(HMLE) cells that undergo an EMT upon the activation of Twist expression (HMLE-Twist-
ER) following treatment with hydroxytamoxifen (OHT) (Mani et al., 2008). Over a 15-day 
treatment with OHT, the HMLE-Twist-ER cells shifted their cell-surface markers from an 
epithelial (CD24high, CD44low) to a mesenchymal (CD24low, CD44high) profile ((Al-Hajj et 
al., 2003), Figure S2C), induced ZEB1 and TWIST1 expression, and suppressed CDH1 
(Figure 2F and 2G). Like the mesenchymal markers, MMS genes such as DPYD and NNMT 
also displayed a progressive increase in mRNA and protein levels over the course of OHT 
treatment (Figure 2F and 2G). Moreover, NAMEC cells, an HMLE-derived cell line that 
spontaneously acquired the mesenchymal state (Tam et al., 2013) (Figure S2D), also 
expressed high levels of several MMS genes (Figure 2F). Lastly, re-analysis of a previous 
expression profiling study comparing HMLE cells expressing an empty vector or Twist 
(Taube et al., 2010) showed that, unlike the majority of metabolic genes, MMS genes were 
upregulated upon EMT induction in culture (Figure 2H). Collectively, these results suggest 
that the EMT program and MMS gene induction are coupled processes.
A FACS-based pooled shRNA screen for MMS genes required for the EMT
To identify which, if any, of the MMS genes play a critical role in the EMT, we developed a 
FACS-based RNAi screen using a pool of 514 lentivirus vector-expressed shRNAs targeting 
42 of the MMS genes, as well as non-expressed control genes (GFP, RFP, Luciferase, and 
LacZ), and non-MMS metabolic genes (Figure S3A). We then induced the EMT in HMLE-
Twist-ER cells expressing the shRNA hairpin library, and after 15 days compared the 
abundance of each hairpin in FACS-sorted epithelial versus mesenchymal cell populations 
isolated using the CD44 and CD24 surface antigens (Figure 3A). We reasoned that 
knockdown (KD) of an EMT-essential gene would cause cells to remain in the epithelial 
state (CD24high/CD44low) even upon OHT treatment. Indeed, hairpins targeting the EMT-
promoting transcription factors ZEB1 and SNAI1 were enriched in the epithelial population 
(Figure 3B). We also found that hairpins against 16 MMS genes were similarly enriched, 
suggesting that knockdown of these genes blocks activation of the EMT program (Figure 
3C). Among the MMS genes, DPYD was a top hit, with 5 out of 12 hairpins scoring in the 
screen (Figure 3B). DPYD is the rate-limiting enzyme of the pyrimidine degradation 
pathway (Amstutz et al., 2011) and is also capable of degrading the chemotherapeutic agent 
5-fluorouracil (5-FU), but the physiological role of this enzyme in cancer cells is unclear 
(Offer et al., 2013).
We wished to rule out the possibility that knockdown of DPYD and the other MMS hit 
genes may block the EMT by affecting the proliferation or viability of epithelial cells. Thus, 
in a parallel experiment, we determined the abundance of each hairpin in HMLE-Twist-ER 
cells before and after a 15-day period of proliferation in the absence of EMT induction 
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(Figure 3A, uninduced day 0 and day 15). As expected, the control hairpins as a group had a 
neutral effect on proliferation (median log2 hairpin abundance ratio = −0.28). Importantly, 
the abundance distributions of the ZEB1, SNAI1, and DPYD hairpins did not differ 
significantly from the control group (Figure 3D), indicating that these hairpins did not affect 
cellular viability or proliferation; by contrast, hairpins targeting ribonucleotide reductase M1 
(RRM1) and thymidylate synthetase (TYMS), which are critical for cell division (Tennant et 
al., 2010), caused a significant anti-proliferative effect (median log2 hairpin abundance ratio 
= −3.23, and −2.4, respectively) (Figure 3D). Therefore, knockdown of DPYD suppressed 
the EMT program without inhibiting the viability or proliferation of epithelial cells, 
suggesting that this enzyme plays a specific role in inducing the mesenchymal cell state.
To validate the identification of DPYD as essential for the EMT, we individually infected 
HMLE-Twist-ER cultures with eight distinct shRNAs targeting DPYD. We found that 
DPYD knockdown, in a dose-dependent manner, decreased the percentage of cells with a 
mesenchymal-like profile (CD24low/CD44high) after 15 days of Twist induction by OHT 
treatment (Figure S3C). DPYD knockdown with the hairpins that most strongly reduced 
DPYD expression (shDPYD_1 and shDPYD_4) (Figure S3D and S3G) did not affect the 
viability of untreated HMLE-Twist-ER cells (Figure S3E), but decreased the percentage of 
OHT-treated cells with a mesenchymal-like profile (Figure S3F). In order to further 
demonstrate the reliability of the screen, we validated another hit from the screen, 
glutathione peroxidase 8 (GPX8) (Figure 3C). As for DPYD, GPX8 hairpins demonstrated a 
similar expression-phenotype relationship (Figure S3H), thus confirming that several MMS 
genes are essential for the EMT program.
DPYD expression promotes the EMT
Next, we further characterized the role of DPYD in the EMT program. In addition to 
inhibiting the EMT-associated changes in cell-surface marker expression (CD24high/
CD44low to CD24low/CD44high) (Figure 4A), DPYD knockdown suppressed the Twist-
induced expression of known mesenchymal markers, as judged by qPCR (Figure 4B), 
immunoblotting (Figure 4C), and immunofluorescence (Figure 4E). Moreover, DPYD 
knockdown suppressed EMT-induced changes in cell morphology (Figure 4D and 4E).
To rule out the possibility that the effects of the DPYD shRNAs are due to off-target effects, 
we restored DPYD levels in shDPYD-expressing HMLE-TwistER cells by ectopically 
expressing the mouse isoform of DPYD (mDPYD), which is 86% identical at the amino acid 
level to the human isoform (Figure S4A) but is unaffected by the shRNAs targeting the 
human DPYD mRNA (Figure S4B). Importantly, mDPYD rescued the effect of shDPYD on 
the expression of cell-surface markers (Figure 4A) and known EMT genes (Figure 4B, 4C 
and 4E) as well as changes in cell morphology (Figure 4D and 4E). DPYD knockdown had a 
similar effect on mesenchymal marker expression in PANC1 pancreatic cancer cells 
engineered to express Twist-ER (Figure S4C), showing that the role of DPYD in EMT 
induction is not restricted to breast tissued-derived cell lines.
As an in vitro functional readout of the EMT, we measured the capacity of HMLE-Twist-ER 
cells to form mammospheres, migrate, and invade, which are unique properties of the 
mesenchymal-like (CD24low/CD44high) but not epithelial (CD24high/CD44low) cells (Mani 
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et al., 2008). DPYD knockdown decreased the efficiency of mammosphere formation 
(Figure 4F and S4D), as well as the capacity of the cells to migrate (Figure 4G and S4E) and 
invade matrigel (Figure 4H). Therefore, blockade of EMT induction by DPYD suppression 
affects multiple in vitro phenotypes of mesenchymal cells.
We then turned our attention to the role of DPYD expression in the EMT program during 
the progression of human cancer cells through specific aspects of the metastatic cascade in 
mice. Extravasation is a key step in metastasis, permitting cancer cells to migrate out of 
capillaries into target tissues (Nieto and Cano, 2012) and recent studies demonstrate that 
Twist-induced EMT promotes tumor cell extravasation (Tsai et al., 2012). To test whether 
DPYD plays a role in the ability of cells to extravasate, we used HMLE-Twist-ER 
transformed with an H-RasG12V oncogene expression vector that also expressed GFP 
(HMLER-TwistER cells). These cells were then infected with hairpins against DPYD 
together with a vector control or mDPYD, induced by OHT to undergo EMT in vitro, and 
injected into the mouse tail vein. As measured by GFP staining, DPYD depletion reduced 
the ability of HMLER-Twist-ER cells to enter the mouse lung by ~95% (Figure 4I and 4J), a 
process that was significantly rescued by the expression of mDPYD (Figure 4I and 4J). 
Thus, DPYD plays an essential role during the lung extravasation of cancer cells that are 
undergoing the EMT.
DPYD activity is essential for its function in the EMT
We asked whether the role of DPYD in the EMT requires its enzymatic activity. 
Accordingly, we tested the ability of a catalytically attenuated mouse DPYD mutant 
(mDPYD-I560S, also known as DPYD*13, which has a 75% reduction in enzymatic activity 
relative to WT (Offer et al., 2013)), to rescue the inhibitory effect of shDPYD_1 on EMT 
induction. Whereas expression of wild-type mDPYD in the presence of shDPYD_1 restored 
the EMT induction following 15 days of OHT treatment, mDPYD-I560S had a greatly 
reduced capacity to rescue CD44/CD24 expression and mammosphere formation, and 
completely failed to restore expression of the EMT-inducing transcription factor ZEB1 
(Figure 5A–C). In addition, while control cells (expressing empty vector) treated with OHT 
for only 10 days displayed an intermediate CD44/CD24 marker expression profile, cell lines 
ectopically expressing either mouse or human DPYD (DPYD-FLAG) displayed higher 
mesenchymal marker expression at this earlier time point (Figure 5D), resembling the 
profile of control cells after a full 15 days of OHT treatment (Figure 5A). Compared to wild-
type DPYD, expression of the mutant DPYD-I560S (human DPYD-I560S-FLAG) had a 
greatly attenuated effect on cell-surface marker expression, mammosphere formation, and 
ZEB1 expression (Figure 5D-F). Thus, the pro-EMT role of DPYD requires DPYD residues 
needed for its full enzymatic activity. Moreover, the accelerated progression of the EMT in 
DPYD-overexpressing cells suggests that the DPYD products may be rate-limiting in EMT.
Cellular dihydropyrimidine levels are elevated during the EMT
Having demonstrated that DPYD enzymatic activity plays a critical role in the EMT 
program, we asked whether its metabolic products increase in abundance during this 
process. To do so, we used liquid chromatography and mass spectrometry (LC-MS) (Büchel 
et al., 2012) to determine the cellular concentration of DPYD substrates (uracil and thymine) 
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and immediate products (dihydrouracil (DHU) and dihydrothymine (DHT)) (Figure 5G) 
(Lohkamp et al., 2010). In HMLE-Twist-ER cells, overexpression or knockdown of DPYD 
resulted in a corresponding ~10-fold increase or decrease, respectively, in the intracellular 
DHU/uracil molar ratio (Figure 5H). Moreover, NAMEC cells exhibited higher DHU/uracil 
and DHT/thymine ratios than HMLE-Twist-ER cells (by 10- and 6-fold, respectively; Figure 
5H and S5A), consistent with the higher endogenous DPYD expression level in the former 
cells (Figure 2F). In addition, OHT treatment of HMLE-Twist-ER cells, which progressively 
upregulates DPYD expression (Figure 2F and 2G), gradually increased the cellular DHU/
uracil molar ratio by 5-fold after 15 days of Twist induction (Figure 5I). DPYD expression 
and DHU/uracil ratios were also correlated in breast cancer and HCC cell lines (Figure 5J 
and 5K). Notably, the higher DHU/uracil molar ratio in MCF7 breast cancer cells compared 
to the other luminal breast cancer cell lines (Figure 5J) correlated with the relatively high 
expression of DPYD in this particular cell line (Figure 2D). Hence, DHU/uracil and DHT/
Thymine ratios correlate closely with DPYD expression levels and mesenchymal character 
in a number of cellular settings, suggesting that DPYD is enzymatically active in the cancer 
cell lines that we examined.
DPYD is normally expressed in the liver, where it is the rate-limiting enzyme of a three-step 
pyrimidine degradation pathway that converts uracil and thymine to β-alanine and 2-methyl-
β-alanine, respectively (Figure 5G) (Lohkamp et al., 2010). In the liver, the immediate 
products of DPYD are further catabolized by dihydropyrimidinase (DPYS) and beta-
ureidopropionase (UPB1) (Van Kuilenburg et al., 2004) (Figure 5G). In contrast, we found 
that HMLE-Twist-ER and NAMEC cells express only DPYD, but not the other components 
of this catabolic pathway (Figure S5B). In addition, unlike that of DPYD, DPYS and UPB1 
expression was not elevated in breast Basal B and high-grade HCC cell lines (Figure S5C). 
These observations explain why the products of DPYD activity can accumulate in 
mesenchymal-like cancer cells, but may not do so in normal liver.
Intracellular dihydropyrimidines are essential for the EMT
To establish the requirement for the immediate products of DPYD in the EMT program, we 
ectopically expressed DPYS-FLAG, which to our knowledge is the only known enzyme that 
uses dihydropyrimidines (DHPs) as substrates (Van Kuilenburg et al., 2010). We found 
DPYS-FLAG to be an active enzyme, as it reduced the intracellular concentration of its 
substrates (DHPs, Figure 6A) while elevating the intracellular abundance of its immediate 
product, 3-ureidopropionate (Figure S6A). After 15 days of Twist induction by OHT 
treatment, DPYS-FLAG expression decreased the percentage of cells with a mesenchymal 
profile (CD24low/CD44high) (Figure 6B), and inhibited the upregulation of mesenchymal 
markers (Figure 6C), and the ability of the cells to migrate (Figure 6D) and form 
mammospheres (Figure 6E). These results provide further evidence that the accumulation of 
DHPs plays a key role in the EMT program.
Next, we asked whether addition of DHU or DHT to culture media could substitute for 
DPYD loss. Indeed, treatment of shDPYD_1 cells with these metabolites at 10 or 100 μM 
resulted in a dose-dependent rescue of mammosphere formation (Figure 6F), whereas the 
DPYD substrate uracil had a significantly smaller effect (Figure S6B), despite the fact that 
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uracil and DHU accumulated to comparable intracellular concentrations (Figure S6C). 
Therefore, the effect of DPYD knockdown on mammosphere formation can be reversed 
either by ectopic expression of active DPYD (Figure 4C and 5C) or by supplementation of 
the cell culture media with its products. Together, these results confirm that the MMS gene 
product DPYD plays a critical role in the EMT via its capacity to generate 
dihydropyrimidines.
Discussion
We identified a mesenchymal metabolic signature (MMS) consisting of 44 metabolic genes 
upregulated in cancers bearing mesenchymal markers. Several of these metabolic genes are 
essential for the EMT, including DPYD, the rate-limiting enzyme of the pyrimidine 
degradation pathway. Remarkably, the expression of DPYD is not required for cell viability 
or proliferation, demonstrating the existence of metabolic processes that specifically enable 
carcinoma cells to acquire mesenchymal-like characteristics. Because these characteristics 
are associated with increased cancer aggressiveness, these findings suggest that DPYD 
activity may play a role in carcinoma progression.
There is a clear difference between the metabolic pathways that are associated with 
proliferation and those upregulated during the EMT. Compared to resting cells, proliferating 
cells upregulate glycolysis and nucleotide biosynthesis pathways (Hu et al., 2013), whereas 
the mesenchymal metabolic signature (MMS) is enriched in glycan biosynthesis genes. 
Glycosylation is thought to be one of the most common covalent protein modifications in 
eukaryotic cells, with a major role in differentiation and mediating cell-cell interactions (Li 
et al., 2013). Because the EMT is accompanied by major changes in cell morphology and 
detachment from the surrounding cells, it is reasonable to assume that a major glycan 
remodeling may occur during the EMT program. Furthermore, glycosylation regulates the 
function of several key players in the EMT, including the products of the SNAI1 and CD44 
genes (Jaggupilli and Elkord, 2012; Park et al., 2010). Thus, we anticipate that future studies 
will further demonstrate an important role for specific glycan remodeling events in both the 
mesenchymal phenotype and in the EMT program.
After executing the EMT program, epithelial-derived cancer cells acquire traits associated 
with high-grade malignancy, including resistance to apoptosis and chemotherapy, 
dedifferentiation, and invasiveness, which can lead to metastatic dissemination from primary 
tumors (Tam and Weinberg, 2013). Thus, inhibiting the EMT may maintain a tumor in a 
lower-grade state, potentially increasing therapeutic efficacy and slowing metastasis. The 
feasibility of manipulating epithelial plasticity is reinforced by studies showing that 
depletion of ZEB1 by RNA interference in mesenchymal-like cells results in a partial 
mesenchymal-epithelial transition (MET), presumably through the induction of CDH1 
expression (Chaffer et al., 2013). However, the development of inhibitors targeting 
transcription factors such as ZEB1 remains a challenge (Singh and Settleman, 2010). By 
contrast, many of the enzymes encoded by the MMS have well-defined active sites that can 
potentially be targeted by small molecules. Here, we demonstrate that DPYD expression and 
activity are essential for the induction of ZEB1 expression, suggesting that the expression of 
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transcriptional drivers of the EMT program can be modulated through inhibition of 
metabolic enzymes such as DPYD.
Many studies have linked DPYD function with acquired tumor resistance to the 
chemotherapeutic agent 5-FU, but the physiologic role of this enzyme in cancer cells is 
unknown (Amstutz et al., 2011). By demonstrating that DPYD plays an essential role in the 
EMT, we provide one of the first indications for its function in cancer. However, there is a 
clear distinction between this function and the normal role of DPYD in the liver. In the 
latter, DPYD functions as the first enzyme in a three-step pathway of pyrimidine 
degradation, whereas we show that in mesenchymal-like cells, the expression of the two 
downstream enzymes (DPYS and UPB1) is not detectable at the mRNA level. Therefore, the 
EMT program reconfigures the pyrimidine degradation pathway in order to use only DPYD, 
presumably because its enzymatic activity fulfills a specific metabolic demand. We suggest 
that this EMT-dependent metabolic rewiring, which activates only selected components of a 
given metabolic pathway, is not exclusive to DPYD, but can potentially occur in other 
MMS-related metabolic processes. Thus, through such rewiring, the EMT may confer novel 
cellular functions to other pathways represented in the MMS as well. Further studies aimed 
at understanding the role of the MMS genes in cancer may reveal novel metabolic processes 
that promote cancer aggressiveness.
The function of DPYD in the EMT is dependent upon its products, the dihydropyrimidines 
(DHPs), DHU and DHT. However, understanding the role of these metabolites in the EMT 
program is challenging, because no biological function has been ascribed the DHPs other 
than as substrates for the enzyme DPYS. One possibility is that DHPs may act as allosteric 
regulators of other enzymes, similar to serine in the case of the glycolytic enzyme pyruvate 
kinase M2 (PKM) (Chaneton et al., 2012), or as receptor ligands, like the citric acid cycle 
intermediates succinate and α-ketoglutarate in the case of the G-protein coupled receptors 
GPR99 and GPR91, respectively (He et al., 2004). In this scenario, the DHPs themselves 
could act as key signaling molecules without further enzymatic processing.
Another potential function for the DHPs is that these pyrimidine bases could be converted to 
pyrimidine deoxynucleosides or nucleosides and thus possibly incorporated into DNA or 
RNA, respectively. Support for this latter possibility comes from previous studies showing 
that genotoxic agents can damage DNA precursors (dNTPs) in the nucleotide pools of 
bacterial cells (Dolinnaya et al., 2013). These chemically altered dNTPs, including the 
deoxynucleotide triphosphate form of DHT (DHdTTP), have been found to be incorporated 
into bacterial genomes (Dolinnaya et al., 2013) and are able to substitute for deoxythymidine 
triphosphate (dTTP) as substrates for the E. coli DNA polymerase I and Klenow fragments 
in vitro (H Ide, 1988; Ide et al., 1987). It remains to be determined whether such modified 
nucleotides can be produced in human cells and, if so, how they affect cellular phenotypes.
Experimental Procedures
Identification of the Metabolic Mesenchymal Signature (MMS) genes
For each metabolic gene, the ratio between the mean expression level in mesenchymal 
(mesenchymal group, Figure 1) and non-mesenchymal cell lines (all other groups) was 
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determined. The mean and standard deviation of all the metabolic gene expression ratios 
was calculated, and all genes upregulated above a 2 fold or below a −2 were classified as 
MMS (Table S2).
Pooled shRNA screen
pLKO.1 lentiviral plasmids encoding shRNAs targeting 74 genes (listed in Table S3)) were 
obtained and combined to generate a plasmid pool (Possemato et al., 2011). HMLE cells 
were infected with the pooled lentivirus at an MOI of 0.2–0.5 so as to ensure that most cells 
contained only one viral integrant. Cells were selected for 3 days with 0.5 mg/ml puromycin, 
after which 106 cells were removed, washed, and frozen at −80°C (Figure 3A, day 0). The 
remaining cells were split into OHT-treated and untreated samples. After 15 days, the OHT-
treated cells were trypsinized, washed with phosphate buffered saline (PBS)+1% inactivated 
fetal calf (IFC) serum, and FACS-sorted using CD44/CD24 antibodies in order to separate 
the mesenchymal and epithelial populations.
Genomic DNA was isolated from all the cells using the QIAampDNA mini kit (Qiagen). To 
amplify the shRNAs encoded in the genomic DNA, PCR was performed for 33 cycles at an 
annealing temperature of 66°C using 3.5 μg of genomic DNA, the primer pair indicated 
below, and DNA polymerase (TAKARA Ex taq, Clontech lab, RR001A). Forward primers 
containing unique 4-nucleotide barcodes were used (see below) so that PCR products 
obtained from many samples could be sequenced together. After purification, the PCR 
products from each cell sample were quantified by ethidium bromide staining (Sigma-
Aldrich, E1510) after gel electrophoresis, pooled in equal proportions, and analyzed by 
high-throughput sequencing (Illumina). The shRNAs from all 4 DNA samples (day 0, day 
15 untreated, day 15 OHT-treated mesenchymal, and day 15 OHT-treated epithelial) were 
sequenced together. Sequencing reads were de-convoluted using GNU Octave software by 
segregating the sequencing data by barcode and matching the shRNA stem sequences to 
those expected to be present in the shRNA pool, allowing for mismatches of up to 3 
nucleotides. The log2 values reported are the average log2 of the fold change in the 
abundance of each shRNA in the mesenchymal-like samples compared to epithelial cells. 
The mean and standard deviation of the control hairpins (GFP, RFP, Luciferase, LacZ) were 
calculated and used to set a cutoff (one standard deviation below the control mean). Every 
gene that had at least two hairpins with a log2 value below the cutoff was considered a hit 
(hairpin ratio list is in Table S4).
Metabolite Extraction
Solvents were obtained from Fisher Scientific and were Optima LC-MS grade except where 
otherwise specified. Cells grown in standard tissue culture plates (~500,000 cells per 
sample) were washed twice in an ice-cold solution of 0.9% NaCl in deionized water, 
followed by extraction on dry ice in 1 mL 80% methanol containing 10ng/mL 
phenylalanine-d8 and valine-d8 (Sigma-Aldrich, 492485 and 486612 respectively) as 
internal standards. The cell mixtures were shaken vigorously on a Vortex mixer for 10 min. 
at 4°C, vacuum-dried, and resuspended in 100 μL LC-MS grade water (Fisher). These 
extracts were then centrifuged at 15,000xg at 4°C for 10 min., and the supernatants were 
passed through a cellulose acetate particulate filter (National Scientific).
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Migration and Invasion Assays
For the migration assay, 50,000 cells were seeded into 24-well cell culture inserts with 8 μm 
pores (BD falcon, 353097). For invasion assay 50,000 cells were seeded on BD Matrigel 
invasion chambers with 8 μm pores (Corning, 62405-744). For both assays, after 20 hours, 
the cells on the upper surface of the filters were removed using cotton swabs. For 
visualization the cells were fixed with 4% PFA in PBS, followed by methanol treatment and 
crystal violet. Three fields per filter were counted. Data are presented as migrated cells per 
filter.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Mesenchymal-like cancer cell lines express a common metabolic gene signature
• Mesenchymal metabolic signature (MMS) genes are upregulated during the 
EMT
• The pyrimidine degradation enzyme DPYD is essential for the EMT
• Accumulation of DPYD products is essential for the EMT
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Figure 1. Based on metabolic gene expression patterns, high-grade carcinoma cell lines co-cluster 
with mesenchymal cells
(A) Metabolic gene expression patterns are sufficient to cluster most, but not all, cancer cell 
lines based on their tissue of origin. Two-way hierarchical clustering of the expression levels 
of 1,704 metabolic genes in 978 different cell lines is presented as a heatmap
(B) Cell lines derived from related cancer types co-cluster based on metabolic gene 
expression patterns. Each row shows all the cell lines in the dataset derived from the 
indicated cancer type. Within each row, each black line represents the position of a cell line 
in the cluster.
(C) Most high-grade hepatocellular carcinoma (HCC) and basal B breast cancer cell lines 
cluster within the mesenchymal group.
(D) Known mesenchymal markers are highly expressed in the mesenchymal group. Cancer 
cell lines were ordered as in (A).
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Figure 2. High expression of mesenchymal metabolic signature (MMS) genes in mesenchymal 
cell lines
(A) Identification of the MMS. For each metabolic gene, the ratio between the mean 
expression level in the mesenchymal group of cell lines and in all other groups (see Figure 
1) was determined and used to rank the genes. Genes that are upregulated (purple, 44 genes) 
or downregulated (blue, 16 genes) by at least 2-fold in mesenchymal relative to non-
mesenchymal cells are highlighted.
(B) Elevated MMS gene expression in mesenchymal cancer cell lines and primary tumors. 
Cancer cell lines and primary tumors were divided into mesenchymal and non-mesenchymal 
groups based on the expression of known mesenchymal markers (Figure 1D and Figure 
S2A). For each metabolic gene, the ratio of the mean expression level between the groups 
was determined. The box plots represent the log2 ratio distribution of MMS genes (purple) 
and all other metabolic genes (gray).
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(C) MMS gene expression is elevated in Basal B breast and high-grade HCC cancer cell 
lines. Box plots represent the expression levels of the MMS genes in the indicated breast 
cancer (green, luminal; red, Basal B) and HCC (blue, low-grade; brown, high-grade) 
subtypes.
(D) Individual validation of MMS mRNA levels in breast cancer (green, luminal; red, Basal 
B) and HCC (blue, low-grade; brown, high-grade) cell lines by quantitative real-time PCR 
(qPCR). Each value represents the mean ± SEM for n=3.
(E) Individual validation of MMS protein levels in the indicated breast cancer and HCC cell 
lines by immunoblotting.
(F) MMS protein upregulation in the same cells as in (G). HMLE-Twist-ER cells were 
treated with hydroxytamoxifen (OHT) to induce an EMT for 15 days. Every three days, 
cellular proteins were isolated and subjected to immunoblotting using the indicated 
antibodies. NAMEC cells are mesenchymal cells derived from HMLE cells (see 
Experimental Procedures).
(G) MMS gene upregulation in an HMLE-Twist-ER inducible EMT system. Every three 
days, cells were collected and mRNA isolated and subjected to qPCR using the indicated 
probes. Each value represents the mean ± SEM.
(H) MMS genes are upregulated during the EMT. Microarray analysis for gene expression 
changes during EMT was described previously (GSE24202,(Taube et al., 2010)). Here the 
same dataset was reanalyzed for the log2 expression ratio of MMS and all other metabolic 
genes between HMLE-Twist-ER cells forced to express Twist and Snai1 (mesenchymal) to 
HMLE-Twist-ER expressing empty vector (epithelial). The box plots represent the log2 ratio 
expression distributions of MMS genes (purple) and all other metabolic genes (gray). The p 
value for the comparison between the two groups was determined using the Student’s T test.
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Figure 3. A FACS-based pooled shRNA screen identifies DPYD as required for EMT
(A) Schematic presentation of the FACS-based pooled shRNA screen. OHT, 
hydroxytamoxifen; gDNA, genomic DNA.
(B) DPYD knockdown (KD) inhibits the EMT. All hairpins from the screen were ranked 
based on the log2 ratio of their abundance in the mesenchymal relative to the epithelial 
population of OHT-induced HMLE-Twist-ER cells after FACS sorting (see Figure 3A). 
Hairpin sub-pools pictured include those targeting control genes (39 hairpins targeting RFP, 
GFP, luciferase, and LacZ), ZEB1 (9 hairpins), SNAI1 (8 hairpins), and DPYD (12 
hairpins). One standard deviation below the mean of the distribution of the control hairpins 
was set as a cutoff (red line). Every hairpin with a log2 ratio below the cutoff was considered 
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a hit. The significance of the differences in distribution between the selected genes and the 
other genes in the screen was quantified using the Student’s T test.
(C) Several of the MMS genes are critical for the EMT. Genes with at least two hairpins 
scoring below the cutoff (see panel B) were classified as hit genes. The numbers in the table 
represent the hit genes as a fraction of the total genes in a given sub-pool.
(D) DPYD KD does not affect cell viability. All hairpins were ranked based on the log2 ratio 
of their abundance in uninduced HMLE-Twist-ER cells on day 15 relative to day 0. The 
same hairpin sub-pools as in (B), with the addition of shRNAs targeting the essential genes 
RRM1 (4 hairpins) and TYMS (5 hairpins), are shown. The significance of the differences 
in distribution between the selected genes and the control genes was quantified using 
Student’s T test.
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Figure 4. DPYD expression is essential for EMT induction
(A) Mouse DPYD expression rescues the effects of DPYD KD on the EMT. HMLE-Twist-
ER cells were infected and treated as indicated followed by FACS analysis for the cell-
surface markers CD24 and CD44. The percentage of cells in each gate is presented (mean ± 
SD).
(B) Mouse DPYD rescues the effects of DPYD KD on mesenchymal gene expression. 
HMLE-Twist-ER cells were infected and treated as indicated. The expression levels of the 
indicated genes were measured using qPCR (mean ± SEM).
(C) Mouse DPYD rescues the effects of DPYD KD on ZEB1 expression. HMLE-Twist-ER 
cells were infected and treated as indicated. Followed by immunoblotting with the indicated 
antibodies.
(D) Mouse DPYD rescues the effects of DPYD KD on cell morphology. HMLE-Twist-ER 
cells were infected and treated as in (B) and visualized with bright-field microscopy. EV, 
empty vector.
(E) Mouse DPYD rescues the effects of DPYD KD on cell morphology and gene 
expression. HMLE-Twist-ER cells were infected and treated as in (B) and the indicated 
proteins were visualized by immunofluorescence.
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(F) Mouse DPYD rescues the effects of DPYD KD on mammosphere formation. 
Quantification of in vitro mammosphere formation by cells treated as in (C). The data are 
reported as the number of mammospheres formed per 500 seeded cells; each value 
represents the mean ± SD for n=6.
(G)Mouse DPYD rescues the effects of DPYD KD on cell migration. HMLE-Twist-ER cells 
were infected and treated as in (B) and their ability to migrate was measured. The data are 
reported as the number of migrated cells per 50,000 seeded cells; each value represents the 
mean ± SD for n=3. EV, empty vector.
(H) Mouse DPYD rescues the effects of DPYD KD on cell invasiveness. HMLE-Twist-ER 
cells were infected and treated as in (B) and their ability to migrate through Matrigel was 
measured. The data are reported as in (G).
(I) DPYD KD inhibits lung extravasation of cancer cells in vivo. HMLER-Twist-ER cells 
expressing the indicated hairpins and ORFs were treated with OHT for 15 days, and then 
injected into the mouse tail vein. After 3 days the number of GFP positive cells in each lung 
was determined by IHC. Each value (●) represents the average of three non-adjacent lung 
sections from a single mouse (5 mice per group).
(J) DPYD KD inhibits lung extravasation of cancer cells in vivo. Representative GFP-
positive cells from the same mouse lungs as in (I) are indicated with arrows. The bottom 
panels show magnifications of the boxed areas in the upper panels.
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Figure 5. DPYD activity is essential for the EMT
(A) Mouse DPYD-I560S fails to rescue the effects of DPYD KD on the EMT. HMLE-
Twist-ER cells were infected and treated as indicated followed by FACS analysis as in 
Figure 4A.
(B) Mouse DPYD-I560S fails to rescue the effects of DPYD KD on ZEB1 expression. 
HMLE-Twist-ER cells were infected and treated as indicated followed by immunoblotting 
with the indicated antibodies.
(C) The I560S mutation prevents the capacity of mDPYD to promote mammosphere 
formation in DPYD KD cells. Cells treated as in (B) were subjected to the in vitro 
mammosphere formation assay as in Figure 4F.
(D) DPYD activity accelerates the EMT. HMLE-Twist-ER cells infected with the indicated 
constructs were either left untreated or treated with OHT for 10 days, followed by FACS 
analysis as in Figure 4A. The percentage of cells in each gate is presented.
(E) Unlike wild-type human DPYD, overexpression of the catalytically attenuated DPYD 
(DPYD-I560S) does not potentiate the Twist-induced ZEB1 upregulation after 10 days of 
OHT treatment. Cells infected with the indicated constructs were either left untreated or 
treated with OHT for 10 days, followed by immunoblotting with the indicated antibodies.
(F) DPYD activity enhances mammosphere formation. Cells treated as in (D) were subjected 
to the in vitro mammosphere formation assay as in Figure 4F.
(G)Schematic presentation of the pyrimidine degradation pathway. Gene names are marked 
in red: DPYD, dihydropyrimidine dehydrogenase (rate-limiting step); DPYS, 
dihydropyrimidinase; UPB1, beta-ureidopropionase.
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(H) Modulation of DPYD expression affects the cellular DHU/uracil molar ratio. DHU and 
uracil levels were measured by liquid chromatography and mass spectrometry (LC-MS) in 
NAMEC or HMLE-Twist-ER cell lines expressing empty vector, DPYD-FLAG or 
shDPYD_1 hairpin. Each value represents the mean ± SD.
(I) The cellular DHU/uracil ratio increases during EMT. HMLE-Twist-ER cells were treated 
with OHT for 15 days. At the indicated time points, samples were collected and subjected to 
LC-MS analysis to determine DHU and uracil levels. The molar concentration ratio between 
the two metabolites in each sample is presented. Each value represents the mean ± SD.
(J) The cellular DHU/uracil ratio is elevated in Basal B relative to luminal breast cancer cell 
lines. The concentrations of DHU and uracil were measured in the indicated breast cancer 
cell lines (green, luminal; red, basal B) using LC-MS. Each value represents the mean ± SD.
(K) The cellular DHU/uracil ratio is elevated in high-grade relative to low-grade HCC cell 
lines. Same as (D), but for HCC cell lines (blue, low-grade; brown, high-grade). Each value 
represents the mean ± SD for n=3.
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Figure 6. DPYS expression inhibits the EMT program
(A) DPYS-FLAG expression reduces the cellular DHT/thymine ratio. HMLE-Twist-ER 
cells were infected and treated as indicated followed by liquid chromatography and mass 
spectrometry (LC-MS) to measure the intracellular DHT and thymine concentration. Each 
value represents the mean ± SD.
(B) DPYS-FLAG expression inhibits the EMT program. HMLE-Twist-ER cells were 
infected and treated as in (A) followed by FACS analysis for the cell-surface markers CD24 
and CD44. The percentage of cells in each gate is presented.
(C) DPYS-FLAG expression reduces the expression level of mesenchymal genes. HMLE-
Twist-ER cells were infected and treated as in (A) and the indicated gene expression levels 
were measured using qPCR.
(D) DPYS-FLAG expression inhibits cell migration. HMLE-Twist-ER cells were infected 
and treated as in (A) and their ability to migrate was determined. The data are reported as in 
Figure 4G.
(E) DPYS-FLAG expression inhibits mammosphere formation. Quantification of in vitro 
mammosphere formation by cells infected and treated as in (A). The data are reported as in 
Figure 4F.
(F) DPYD products rescue the effect of DPYD KD on mammosphere formation. HMLE-
Twist-ER cells expressing shDPYD_1 were treated with the indicated concentrations of 
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DHU or DHT and subjected to the in vitro mammosphere formation assay as in (E). The 
data are reported as in Figure 4F.
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Table 1
The mesenchymal metabolic signature genes, classified by metabolic pathway
Genes marked in bold are upregulated in mesenchymal cells. Underlined genes are rate-limiting enzymes.
Metabolic Pathways Metabolic Enzymes
Nucleotide pyrimidine degradation DPYDa,b
other AK5,a ENPP1,a NT5Ea
Lipid triacylglycerol degradation MGLLa
cholesterol TM7SF2, AKR1B1a
sphingosine SPHK1,a UGCGa
signaling ENPP2, a PPAP2B,a PPAPDC1A,a PDE1C,a PLCB4,a PTGR1,a PIK3C2B, PLCG2, 
ALDH1A1, PIP5K1B
Amino Acid branched amino acid degradation BCAT1a
amino acid degradation CYP1B1a
tetrahydrobiopterin biosynthesis GCH1
Carbon TCA cycle CYBRD,a COX7A1,a CYBA
Redox glutathione MGST1,a GPX8,a GPX2
Glycan beta-galactose ST6GAL1, GLB1L2
dermatan sulfate DSE,a DSELa
heparin sulfate HS3ST3A1,a EXT1a
sulfatases ARSJ,a SULF1,a PAPSS2a
glcNac GFPT2, a,b GALNT10,a UAP1a
glycan GXYLT2,a GBE1,a GLT8D2,a GALNT3
hyaluronan HAS2a
glyco protein PAM,a CHI3L1a
other B3GNT9,a MFNG, HPDL
Cofactor nicotinamide AOX1,a NNMT,a QPRT
Other MICAL2,a MME,a DDAH1,a MSRB3,a CA12,a PTER, CA2
TCA, tricarboxylic acid; GlcNAc, N-acetylglucosamine.
a
These genes are upregulated in mesenchymal cells.
b
These genes are rate-limiting enzymes.
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